CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference
Portfolio Pulse from
CalciMedica Inc. presented data from a post-hoc analysis of the Phase 2 CARDEA trial, showing a 62.7% reduction in mortality at day 30 for patients treated with Auxora in severe COVID-19 pneumonia cases with AKI. This effect persisted through day 60.
March 04, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CalciMedica's Auxora demonstrated a significant reduction in mortality in severe COVID-19 pneumonia patients with AKI, potentially boosting investor confidence.
The significant reduction in mortality rates for patients treated with Auxora in the CARDEA trial is a positive development for CalciMedica. This could lead to increased investor confidence and a potential rise in stock price due to the promising results in a critical area of COVID-19 treatment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100